Monberg MJ - Search Results

1

Comparison of advanced ovarian cancer patients treated with or without bevacizumab in the US Community Oncology Clinics.

DeClue RW, Szamreta EA, Gautam S, Fisher MD, Monberg MJ. DeClue RW, et al. Among authors: monberg mj. Future Oncol. 2023 May;19(16):1113-1124. doi: 10.2217/fon-2022-0955. Epub 2023 May 12. Future Oncol. 2023. PMID: 37170823

2

Patient profiles, treatment patterns, and outcomes among persistent, recurrent, or metastatic cervical cancer patients under routine care in the United States.

Gokhale M, Yu R, Monberg M, Tekin C, Chen L, DeClue RW, Knapp K, Lal LS. Gokhale M, et al. Cancer Treat Res Commun. 2023;36:100726. doi: 10.1016/j.ctarc.2023.100726. Epub 2023 Jun 7. Cancer Treat Res Commun. 2023. PMID: 37301127 Free article.

3

The burden of ovarian cancer in the USA from 2007 to 2018: evidence from the Medical Expenditure Panel Survey.

Szamreta EA, Wang WJ, Shah R, Corman S, Monberg M. Szamreta EA, et al. Future Oncol. 2023 Jun;19(19):1331-1342. doi: 10.2217/fon-2022-1072. Epub 2023 Jul 21. Future Oncol. 2023. PMID: 37476966

4

Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting.

Chase DM, Annavarapu S, Tseng WY, Shi J, Szamreta E, Monberg M. Chase DM, et al. Gynecol Oncol. 2024 Jan;180:79-85. doi: 10.1016/j.ygyno.2023.11.016. Epub 2023 Dec 5. Gynecol Oncol. 2024. PMID: 38056115

5

Prognosis and conditional survival among women with newly diagnosed ovarian cancer.

Szamreta EA, Monberg MJ, Desai KD, Li Y, Othus M. Szamreta EA, et al. Among authors: monberg mj. Gynecol Oncol. 2024 Jan;180:170-177. doi: 10.1016/j.ygyno.2023.11.018. Epub 2024 Jan 10. Gynecol Oncol. 2024. PMID: 38211405

6

Impact of the Coronavirus Disease 2019 pandemic on neoadjuvant chemotherapy use in patients diagnosed with epithelial type ovarian cancer.

Mukherjee A, Shammas N, Xu L, Cannavale KL, Gilfillan AD, Szamreta EA, Monberg M, Hodeib M, Chao CR. Mukherjee A, et al. Front Oncol. 2024 Mar 27;14:1290719. doi: 10.3389/fonc.2024.1290719. eCollection 2024. Front Oncol. 2024. PMID: 38601762 Free PMC article.

7

Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.

Elsea D, Muston D, Fan L, Mihai A, Meng Y, Kasle A, Monberg M. Elsea D, et al. Target Oncol. 2023 Jul;18(4):531-541. doi: 10.1007/s11523-023-00966-6. Epub 2023 May 26. Target Oncol. 2023. PMID: 37233868

8

Characteristics, treatment patterns, and outcomes in patients with high-risk locally advanced cervical cancer.

Coutinho F, Gokhale M, Doran C, Monberg M, Yamada K, Chen L. Coutinho F, et al. Cancer Treat Res Commun. 2024;39:100800. doi: 10.1016/j.ctarc.2024.100800. Epub 2024 Feb 25. Cancer Treat Res Commun. 2024. PMID: 38430610 Free article.

9

Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States.

Monk BJ, van Mens S, Hale O, Boer J, van Hees F, Swami S, Muston D, Tekin C, Keefe S, Monberg M. Monk BJ, et al. Oncol Ther. 2024 Nov 5. doi: 10.1007/s40487-024-00311-5. Online ahead of print. Oncol Ther. 2024. PMID: 39499492 Free article.

10

Patterns of use of primary and first-line chemotherapy for recurrence among patients with cervical cancer.

Diggs A, Huang Y, Melamed A, Szamreta E, Monberg MJ, Hershman D, Wright JD. Diggs A, et al. Among authors: monberg mj. Int J Gynecol Cancer. 2024 Jul 1;34(7):1001-1010. doi: 10.1136/ijgc-2023-004860. Int J Gynecol Cancer. 2024. PMID: 38851239

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters